Introduction {#section5-1758835920928214}
============

Nasopharyngeal carcinoma (NPC) is a unique malignancy arising from the epithelial tissues of the nasopharynx and associated with Epstein--Barr virus (EBV) infection in most cases.^[@bibr1-1758835920928214]^ Based on the findings of several prospective randomized trials and meta-analyses, radiotherapy (RT) in combination with cisplatin-based concurrent chemotherapy is the standard of care for previously untreated locoregionally advanced NPC.^[@bibr2-1758835920928214][@bibr3-1758835920928214][@bibr4-1758835920928214]--[@bibr5-1758835920928214]^ The National Comprehensive Cancer Network guidelines recommend RT concurrent with cisplatin 100 mg/m² every 3 weeks for patients with stage II--IVB disease. However, concurrent chemotherapy could increase treatment-related toxicities and decrease treatment compliance, leading discontinuation of RT in some patients. Discontinuing or prolonging treatment can reduce RT efficacy.^[@bibr6-1758835920928214]^ Moreover, the rationale of concurrent chemotherapy with RT in the management of NPC has been largely derived from experience with conventional RT. In the intensity-modulated radiation therapy (IMRT) era, the optimal strategy for combining the use of chemotherapy and RT has not been sufficiently addressed.

The addition of induction chemotherapy (IC) to the previously established regimen is an attractive multidisciplinary approach.^[@bibr7-1758835920928214],[@bibr8-1758835920928214]^ Theoretically, changing concurrent chemotherapy to IC may improve treatment tolerance and help in the early eradication of potential micrometastases. Furthermore, early tumor shrinkage could help attain better coverage of the gross tumor and optimize the design of the RT plan.^[@bibr9-1758835920928214]^ Nevertheless, the therapeutic value of IC followed by IMRT alone has not been fully evaluated.

In this study, we established a nomogram model to improve prediction accuracy compared with clinical risk factors for survival in stage II--IVB NPC. Then, applying this nomogram, patients were divided into different risk groups and the efficacy of concurrent chemoradiotherapy (CCRT) *versus* IC followed by RT was evaluated in patients from different risk groups. The data may provide an additional dimension for risk stratification and individualized therapy.

Patients and methods {#section6-1758835920928214}
====================

Patients {#section7-1758835920928214}
--------

From October 2007 to October 2013, 1824 consecutive previously untreated patients with biopsy-confirmed NPC were identified in our study institute. The eligibility criteria were as follows: (a) age ⩾18 years; (b) stage II--IVB disease according to the 7th edition of the International Union Against Cancer/American Joint Committee on Cancer staging system; (c) score of 0 or 1 with the Eastern Cooperative Oncology Group (ECOG) performance status grade; (d) treatment with IMRT; (e) administration of CCRT or IC plus RT; (f) complete data of pretreatment plasma EBV DNA level; and (g) adequate hematological, liver and renal function. Patients who were administered previous treatment for NPC, the presence of a distant metastasis, pregnancy, lactating women, or with a prior malignancy were excluded from the study. In total, 1814 eligible patients were included for analysis. This study was approved by the Clinical Research Committee of the study institute (approved number, GZR2014-069) and written informed consent was required when the patients were admitted to receive treatment as a general standard procedure for patients treated in our institute.

Pretreatment assessment {#section8-1758835920928214}
-----------------------

Before treatment, all patients underwent complete physical examination, fiberoptic nasopharyngoscopy, and laboratory work-up including complete blood count, biochemical profile, and plasma level of EBV DNA measured by real-time quantitative polymerase chain reaction (PCR).^[@bibr10-1758835920928214],[@bibr11-1758835920928214]^ Magnetic resonance imaging (MRI) of the nasopharynx and neck, chest radiograph, abdominal sonography, electrocardiography and bone scan or 18 F-fluorodeoxyglucose positron emission tomography/computed tomography scans were carried out for accurate disease staging.

Treatment {#section9-1758835920928214}
---------

All patients were treated with IMRT and a simultaneously integrated boost was mandatory in this study. The IMRT plan was designed according to previous studies, and treatment administration was done following the general principle of our institute (see [supplemental materials](https://journals.sagepub.com/doi/suppl/10.1177/1758835920928214)). A total of 1331 (73.4%) patients received concurrent cisplatin (100 mg/m^2^) chemotherapy on days 1, 22 and 43 of RT; 483 (26.6%) patients received induction TPF (cisplatin (75 mg/m^2^, day 1) and docetaxel (75 mg/m^2^, day 1) with 5-fluorouracil (750 mg/m^2^, 96 h continuous intravenous infusion)) or PF (cisplatin (80 mg/m^2^, day 1) with 5-fluorouracil (800--1000 mg/m^2^, 96 h of continuous intravenous infusion)) chemotherapy,^[@bibr10-1758835920928214],[@bibr12-1758835920928214]^ but without concurrent chemotherapy.

Outcome and follow-up {#section10-1758835920928214}
---------------------

The primary endpoint of the study was overall survival (OS), which was defined as the time from the start of treatment until death from any cause or patient censoring at the last follow-up. Secondary endpoints included progression-free survival (PFS), calculated from the start of treatment to the date of first failure at any site or death from any cause or patient censoring at last follow-up; distant metastasis-free survival (DMFS), calculated from the start of treatment to the date of distant relapse or patient censoring at the date of last follow-up and toxicity. After treatment, patients were followed up at least every 3 months for the first 3 years and every 6 months thereafter or until death. Acute toxicities were classified according to the Common Toxicity Criteria for Adverse Events version 4.0 and late radiotherapy-related toxic effects were assessed and graded based on the Radiation Therapy Oncology Group/European Organization for Research and Treatment of cancer morbidity scoring schema.

Statistical analysis {#section11-1758835920928214}
--------------------

Statistical analyses were performed using SPSS version 24.0 (SPSS, Chicago, IL, USA) and R version 3.5.0 ([www.r-project.org](http://www.r-project.org)). Categorical variables were compared with the χ^[@bibr2-1758835920928214]^ test or Fisher's exact test. The Kaplan--Meier method was used to estimate the time-to-event endpoints, and survival curves were compared using the log-rank test. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated with the Cox proportional hazards model. Multivariate analyses with Cox proportional hazards models were performed to evaluate the potential prognostic factors. All statistical testing was two-sided, and a *p* value less than 0.05 was considered significant. Forest plots were generated to present adjusted HRs and 95% CIs of the potential prognostic factors for OS, PFS and DMFS. In addition, nomograms were formulated based on the results of multivariable Cox regression analyses. The selection of the final prediction model was performed with a backward step-down selection process with the Akaike information criterion.^[@bibr13-1758835920928214]^ The performance of nomograms was assessed by the concordance index (C-index) and evaluated by comparing the nomogram-predicted *versus* nomogram-observed Kaplan--Meier estimates of survival probability. A larger C-index indicated a greater predictive accuracy. The total points of each patient were calculated according to the established nomograms.

Results {#section12-1758835920928214}
=======

The baseline demographic and clinical characteristics of 1814 patients are listed in [Table 1](#table1-1758835920928214){ref-type="table"}. After a median follow-up of 77 months (range: 1--152 months), 288 patients died, 352 patients developed disease progression, and 253 patients exhibited distant metastasis.

###### 

Baseline characteristics.

![](10.1177_1758835920928214-table1)

                                  Total patients        Low-risk group        Intermediate-risk group   High-risk group                                                                                                                                     
  ------------------------------- --------------------- --------------------- ------------------------- --------------------- --------------------- ------- --------------------- --------------------- ------- --------------------- --------------------- ---------
  Characteristic                  No. of patients (%)   No. of patients (%)                             No. of patients (%)   No. of patients (%)           No. of patients (%)   No. of patients (%)           No. of patients (%)   No. of patients (%)   
  Total                           1331                  483                                             488                   115                           419                   140                           424                   228                   
  **Age, years**                                                              0.142                                                                 0.403                                               0.354                                               0.765
  18--29                          73 (5.5%)             34 (7.0%)                                       49 (10.0%)            18 (15.7%)                    17 (4.1%)             9 (6.4%)                      7 (1.7%)              7 (3.1%)              
  30--39                          307 (23.1%)           98 (20.3%)                                      145 (29.7%)           36 (31.3%)                    122 (29.1%)           38 (27.1%)                    40 (9.4%)             24 (10.5%)            
  40--49                          496 (37.3%)           163 (33.7%)                                     205 (42.0%)           43 (37.4%)                    141 (33.7%)           44 (31.4%)                    150 (35.4%)           76 (33.3%)            
  50--59                          318 (23.9%)           125 (25.9%)                                     84 (17.2%)            18 (15.7%)                    114 (27.2%)           45 (32.1%)                    120 (28.3%)           62 (27.2%)            
  \>60                            137 (10.3%)           63 (13.0%)                                      5 (1.0%)              0 (0.0%)                      25 (6.0%)             4 (2.9%)                      107 (25.2%)           59 (25.9%)            
  **Gender**                                                                  0.963                                                                 0.667                                               0.028                                               0.111
  Female                          360 (27.0%)           131 (27.2%)                                     231 (47.3%)           57 (49.6%)                    87 (20.8%)            42 (30.0%)                    42 (9.9%)             31 (14.1%)            
  Male                            971 (73.0%)           351 (72.8%)                                     257 (52.7%)           58 (50.4%)                    332 (79.2%)           98 (70.0%)                    382 (90.1%)           195 (85.9%)           
  **Histology, WHO type**                                                     0.187                                                                 0.634                                               0.210                                               0.387
  I                               2 (0.2%)              3 (0.6%)                                        1 (0.2%)              0 (0.0%)                      0 (0.0%)              1 (0.7%)                      1 (0.2%)              2 (0.9%)              
  II                              46 (3.5%)             20 (4.1%)                                       16 (3.3%)             2 (1.7%)                      15 (3.6%)             7 (5.0%)                      15 (3.5%)             11 (4.8%)             
  III                             1283 (96.4%)          460 (95.2%)                                     471 (96.5%)           113 (98.3%)                   404 (96.4%)           132 (94.3%)                   408 (96.2%)           215 (94.3)            
  **T stage**                                                                 \<0.001                                                               0.064                                               0.343                                               0.008
  T1                              86 (6.5%)             19 (3.9%)                                       51 (10.5%)            13 (11.3%)                    23 (5.5%)             4 (2.9%)                      12 (2.8%)             2 (0.9%)              
  T2                              243 (18.3%)           87 (18.0%)                                      95 (19.5%)            29 (25.2%)                    84 (20.0%)            29 (20.7%)                    64 (15.1%)            29 (12.8%)            
  T3                              793 (59.6%)           238 (49.4%)                                     323 (66.2%)           63 (54.8%)                    270 (64.4%)           87 (62.1%)                    200 (47.2%)           88 (38.8%)            
  T4                              209 (15.7%)           138 (28.6%)                                     19 (3.9%)             10 (8.7%)                     42 (10.0%)            20 (14.3%)                    148 (34.9%)           108 (47.6%)           
  **N stage**                                                                 \<0.001                                                               0.243                                               0.107                                               0.022
  N0                              197 (14.8%)           54 (11.2%)                                      140 (28.7%)           34 (29.6%)                    42 (10.0%)            13 (9.3%)                     15 (3.5%)             7 (3.1%)              
  N1                              582 (43.7%)           160 (33.1%)                                     277 (56.8%)           57 (49.6%)                    181 (43.2%)           51 (36.4%)                    124 (29.2%)           52 (22.8%)            
  N2                              443 (33.3%)           187 (38.7%)                                     64 (13.1%)            23 (20.0%)                    170 (40.6%)           59 (42.1%)                    209 (49.3%)           105 (46.1%)           
  N3                              109 (8.2%)            82 (17.0%)                                      7 (1.4%)              1 (0.9%)                      26 (6.2%)             17 (12.1%)                    76 (17.9%)            64 (28.1%             
  **Overall stage**                                                           \<0.001                                                               0.076                                               0.056                                               \<0.001
  II                              154 (11.6%)           38 (7.9%)                                       108 (22.1%)           29 (25.2%)                    36 (8.6%)             9 (6.4%)                      10 (2.4%)             0                     
  III                             867 (65.1%)           238 (49.3%)                                     353 (72.3%)           74 (64.3%)                    315 (75.2%)           94 (67.1%)                    199 (46.9%)           70 (30.7%)            
  IVa                             201 (15.1%)           125 (25.9%)                                     20 (4.1%)             11 (9.6%)                     42 (10.0%)            20 (14.3%)                    139 (32.8%)           94 (41.2%)            
  IVb                             109 (8.2%)            82 (17.0%)                                      7 (1.4%)              1 (0.9%)                      26 (6.2%)             17 (12.1%)                    76 (17.9%)            64 (28.1%)            
  **Smoking**                                                                 0.514                                                                 0.317                                               0.073                                               0.178
  No                              832 (62.5%)           310 (64.2%)                                     378 (77.5%)           94 (81.7%)                    258 (61.6%)           98 (70.0%)                    192 (46.2%)           118 (51.8%)           
  Yes                             499 (37.5%)           173 (35.8%)                                     110 (22.5%)           21 (18.3%)                    161 (38.4%)           42 (30.0%)                    228 (53.8%)           110 (48.2%)           
                                                                              0.350                                                                 0.784                                               0.068                                               
  No                              1178 (88.5%)          435 (90.1%)                                     433 (88.7%)           101 (87.8%)                   363 (86.6%)           130 (92.9%)                   382 (90.1%)           204 (89.5%)           
  Yes                             153 (11.5%)           48 (9.9%)                                       55 (11.3%)            14 (12.2%)                    56 (13.4%)            10 (7.1%)                     42 (9.9%)             24 (10.5%)            
  **EBV DNA level (copies/ml)**   \<0.001                                                               0.233                                               0.395                                               0.844                                       
  \<1000                          623 (46.8%)           172 (35.6%)                                     392 (80.3%)           92 (80.0%)                    175 (41.8%)           55 (39.3%)                    56 (13.2%)            25 (11.0%)            
  1000--9999                      353 (26.5%)           147 (30.4%)                                     73 (15.0%)            22 (19.1%)                    152 (36.3%)           52 (37.1%)                    128 (30.2%)           73 (32.0%)            
  10000--99999                    236 (17.7%)           111 (23.0%)                                     20 (4.1%)             1 (0.9%)                      72 (17.2%)            30 (21.4%)                    144 (34.0%)           80 (35.1%)            
  100000--999999                  101 (7.6%)            41 (8.5%)                                       3 (0.6%)              0 (0.0%)                      20 (4.8%)             3 (2.1%)                      78 (18.4%)            38 (16.7%)            
  ⩾1000000                        18 (1.4%)             12 (2.5%)                                       0 (0.0%)              0 (0.0%)                      0 (0.0%)              0 (0.0%)                      18 (4.2%)             12 (5.3%)             

CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiotherapy.

Nomogram development {#section13-1758835920928214}
--------------------

Multivariable analyses demonstrated that age, gender, T stage, N stage and plasma EBV DNA levels were independent prognostic factors for all endpoints ([Figure 1](#fig1-1758835920928214){ref-type="fig"} and [Supplemental Appendix Table 2](https://journals.sagepub.com/doi/suppl/10.1177/1758835920928214)). Hence, we built nomograms to predict the 3 and 5-year OS, PFS and DMFS using the aforementioned variables. The prognostic nomograms provided a good accuracy for predicting OS, PFS and DMFS with corresponding C-index values of 0.71 (95% CI 0.67--0.76), 0.70 (95% CI 0.66--0.75) and 0.71 (95% CI 0.66--0.75), respectively. The calibration plots for the probabilities of survival showed a good agreement between prediction by nomogram and actual observation ([Figure 2](#fig2-1758835920928214){ref-type="fig"}).

![Forest plots of the multivariate association of clinicopathological characteristics with overall survival (A), progression-free survival (B) and distant metastasis-free survival (C).](10.1177_1758835920928214-fig1){#fig1-1758835920928214}

![Nomograms and calibration curves for predicting the 3 and 5-year overall survival (A, D, G), progression-free survival (B, E, H) and distant metastasis-free survival (C, F, I).](10.1177_1758835920928214-fig2){#fig2-1758835920928214}

Risk stratification {#section14-1758835920928214}
-------------------

Eligible patients in our study were divided into three different risk groups according to tertiles (105 and 137) of total scores calculated by the nomogram for OS---low-risk group (total scores ⩽105 points), intermediate-risk group (105 \< total score ⩽137 points) and high-risk group (total score \>137 points). The characteristics of patients treated with different methods in different risk groups are demonstrated in [Table 1](#table1-1758835920928214){ref-type="table"}. Survival curves were significantly segregated among patients in different risk groups for 5-year OS (*p* \< 0.001), PFS (*p* \< 0.001) and DMFS (*p* \< 0.001) ([Figure 3](#fig3-1758835920928214){ref-type="fig"} and [Supplemental Appendix Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1758835920928214)).

![Results of comparison among patients in different risk groups with regard to the overall survival (A), progression-free survival (B) and distant metastasis-free survival (C).](10.1177_1758835920928214-fig3){#fig3-1758835920928214}

Relationship between treatment methods and survival outcome in each risk group {#section15-1758835920928214}
------------------------------------------------------------------------------

In the low-risk group, no statistically significant survival differences were observed between patients treated with IC plus RT and CCRT (5-year OS, 97.3% *versus* 95.6%, *p* = 0.642; 5-year PFS, 95.9% *versus* 95.6%, *p* = 0.325; and 5-year DMFS, 97.2% *versus* 94.8%, *p* = 0.339) ([Figure 4](#fig4-1758835920928214){ref-type="fig"}). Similarly, patients treated with IC plus RT in the intermediate-risk group had no significant better survival than those in the CCRT group (5-year OS, 87.6% *versus* 89.7%, *p* = 0.381; 5-year PFS, 87.6% *versus* 89.0%, *p* = 0.160; and 5-year DMFS, 87.2% *versus* 89.3%, *p* = 0.628) ([Figure 4](#fig4-1758835920928214){ref-type="fig"}). However, in the high-risk group, IC plus RT had an unfavorable 5-year OS (71.0% *versus* 77.2%, *p* = 0.022) and PFS (69.4.0% *versus* 75.4%, *p* = 0.019) compared with CCRT, except for the 5-year DMFS (74.2% *versus* 77.6%, *p* = 0.376) ([Figure 4](#fig4-1758835920928214){ref-type="fig"}).

![Kaplan--Meier curves of overall survival (A, B, C), progression free-survival (D, E, F) and distant metastasis-free survival (G, H, I) in patients treated with CCRT and IC plus RT in different risk groups.](10.1177_1758835920928214-fig4){#fig4-1758835920928214}

Toxicities {#section16-1758835920928214}
----------

During and after treatment, 772 (58%) patients from the CCRT group and 254 (53.8%) from the IC plus RT group experienced grade ⩾3 toxicities (*p* = 0.040). In the low and intermediate-risk groups, we recorded a higher frequency of grade 3 or 4 vomiting (*p* = 0.037 and *p* \< 0.001, respectively), nausea (*p* = 0.027 and *p* = 0.003, respectively) and mucositis (*p* = 0.005 *p* = 0.036, respectively) in the CCRT group than in the IC plus RT group, whereas the frequency of grade 3 or 4 leucopenia (*p* = 0.054 and *p* = 0.017, respectively) and neutropenia (*p* = 0.001 and *p* \< 0.001, respectively) was higher in the IC plus RT group than in the CCRT group ([Table 2](#table2-1758835920928214){ref-type="table"}). In the high-risk group, the proportion of patients with grade 3 or 4 vomiting (*p* = 0.001) and nausea (*p* = 0.017) was also significantly higher in the CCRT group than in the IC plus RT group, while the occurrence of grade 3 or 4 neutropenia (*p* \< 0.001) was higher in the IC plus RT group ([Table 2](#table2-1758835920928214){ref-type="table"}). After completion of treatment, patients in the CCRT group had a higher frequency of grade 3 or 4 late hearing loss than patients in the IC plus RT group (*p* = 0.03 in intermediate-risk group) ([Table 2](#table2-1758835920928214){ref-type="table"}).

###### 

Acute and late toxicities in patients treated with CCRT and IC plus RT in different risk groups.

![](10.1177_1758835920928214-table2)

                             Low-risk group   Intermediate-risk group   High-risk group                                                                                                                                                                                                                                                                                   
  -------------------------- ---------------- ------------------------- ----------------- ------------ ---------- ---------------------------------------------------------- ------------- ------------ ------------- ------------ ---------- ---------------------------------------------------------- ------------- ------------ ------------- ------------ ---------- ----------------------------------------------------------
  Leucopenia                 355 (72.7%)      60 (12.3%)                90 (78.3%)        22 (19.1%)   0.226      0.054                                                      300 (71.6%)   50 (11.9%)   108 (77.1%)   28 (20.0%)   0.201      0.017                                                      313 (73.8%)   64 (15.1%)   185 (81.1%)   38 (16.7%)   0.036      0.598
  Neutropenia                228 (46.7%)      20 (4.1%)                 61 (53.0%)        14 (12.2%)   0.222      0.001                                                      194 (46.3%)   29 (6.9%)    89 (63.6%)    28 (20.0%)   \<0.001    \<0.001                                                    214 (50.5%)   35 (8.3%)    142 (62.3%)   45 (19.7%)   0.004      \<0.001
  Anaemia                    204 (41.8%)      9 (1.8%)                  51 (44.3%)        0 (0.0%)     0.619      0.219                                                      159 (37.9%)   15 (3.6%)    59 (42.1%)    3 (2.1%)     0.378      0.577                                                      196 (46.2%)   17 (4.0%)    110 (48.2%)   8 (3.5%)     0.622      0.751
  Thrombocytopenia           96 (19.7%)       11 (2.3%)                 25 (21.7%)        4 (3.5%)     0.619      0.670                                                      89 (21.2%)    15 (3.6%)    31 (22.1%)    2 (1.4%)     0.822      0.318                                                      104 (24.5%)   26 (6.1%)    52 (22.8%)    8 (3.5%)     0.623      0.151
  ALT increased              65 (13.3%)       6 (1.2%)                  26 (22.6%)        2 (1.7%)     0.012      1                                                          50 (11.9%)    1 (0.2%)     25 (17.9%)    2 (1.4%)     0.075      0.317                                                      54 (12.7%)    4 (0.9%)     35 (15.4%)    2 (0.9%)     0.354      1
  AST increased              49 (10.0%)       4 (0.8%)                  15 (13%)          0 (0.0%)     0.347      0.594                                                      36 (8.6%)     0 (0.0%)     16 (11.4%)    1 (0.7%)     0.317      0.250                                                      36 (8.5%)     1 (0.2%)     27 (11.8%)    2 (0.9%)     0.167      0.584
  Total bilirubin            95 (19.5%)       15 (3.1%)                 8 (7.0%)          1 (0.9%)     0.001      0.317                                                      64 (15.3%)    10 (2.4%)    15 (10.7%)    3 (2.1%)     0.180      1                                                          84 (19.8%)    9 (2.1%)     16 (7.0%)     3 (1.3%)     \<0.001    0.671
  Total protein              24 (4.9%)        0 (0.0%)                  3 (2.6%)          0 (0.0%)     0.408      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   18 (4.3%)     0 (0.0%)     3 (2.1%)      0 (0.0%)     0.366      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   34 (8.0%)     0 (0.0%)     18 (7.9%)     0 (0.0%)     0.956      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^
  BUN increase               9 (1.8%)         1 (0.2%)                  0 (0.0%)          0 (0.0%)     0.219      1                                                          6 (1.4%)      0 (0.0%)     1 (0.7%)      0 (0.0%)     0.824      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   14 (3.3%)     0 (0.0%)     3 (1.3%)      0 (0.0%)     0.208      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^
  Creatinine increase        70 (14.3%)       1 (0.2%)                  9 (7.8%)          0 (0.0%)     0.062      1                                                          67 (16.0%)    0 (0.0%)     14 (10.0%)    0 (0.0%)     0.081      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   83 (19.6%)    1 (0.2%)     17 (7.5%)     0 (0.0%)     \<0.001    1
  Vomiting                   390 (79.9%)      80 (16.4%)                74 (64.3%)        10 (8.7%)    \<0.001    0.037                                                      347 (82.8%)   80 (19.1%)   101 (72.1%)   6 (4.3%)     0.006      \<0.001                                                    328 (77.4%)   65 (15.3%)   144 (63.2%)   15 (6.6%)    \<0.001    0.001
  Nausea                     368 (75.4%)      46 (9.4%)                 70 (60.9%)        3 (2.6%)     0.002      0.027                                                      314 (74.9%)   40 (9.5%)    82 (58.6%)    2 (1.4%)     \<0.001    0.003                                                      321 (75.7%)   33 (7.8%)    132 (57.9%)   7 (3.1%)     \<0.001    0.017
  Mucositis                  430 (88.1%)      113 (23.2%)               100 (87.0%)       13 (11.3%)   0.732      0.005                                                      376 (89.7%)   98 (23.4%)   118 (84.3%)   21 (15.0%)   0.081      0.036                                                      372 (87.7%)   91 (21.5%)   194 (85.1%)   41 (18.0%)   0.341      0.292
  Dermatitis                 356 (73.0%)      17 (3.5%)                 86 (74.8%)        1 (0.9%)     0.690      0.239                                                      314 (74.9%)   9 (2.1%)     95 (67.9%)    4 (2.9%)     0.102      0.874                                                      317 (74.8%)   15 (3.5%)    153 (67.1%)   3 (1.3%)     0.038      0.161
  Hypokalaemia               80 (16.4%)       12 (2.5%)                 10 (8.7%)         0 (0.0%)     0.037      0.136                                                      50 (11.9%)    8 (1.9%)     18 (12.9%)    1 (0.7%)     0.772      0.559                                                      61 (14.4%)    6 (1.4%)     27 (11.8%)    4 (1.8%)     0.364      0.998
  Hyponatraemia              79 (16.2%)       1 (0.2%)                  10 (8.7%)         0 (0.0%)     0.042      1                                                          87 (20.8%)    2 (0.5%)     19 (13.6%)    0 (0.0%)     0.060      0.624                                                      107 (25.2%)   2 (0.5%)     47 (20.6%)    0 (0.0%)     0.185      0.544
  Hypocalcaemia              6 (1.2%)         0 (0.0%)                  0 (0.0%)          0 (0.0%)     0.366      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   1 (0.2%)      0 (0.0%)     0 (0.0%)      0 (0.0%)     1          ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   3 (0.7%)      0 (0.0%)     1 (0.4%)      1 (0.4%)     1          0.350
  Late toxicities            All grades       Grade 3--4                All grades        Grade 3--4   Grade ⩾1   Grade ⩾3                                                   All grades    Grade 3--4   All grades    Grade 3--4   Grade ⩾1   Grade ⩾3                                                   All grades    Grade 3--4   All grades    Grade 3--4   Grade ⩾1   Grade ⩾3
  Hearing loss               109 (22.4%)      28 (5.7%)                 11 (9.6%)         6 (5.2%)     0.002      0.828                                                      88 (21.0%)    23 (5.5%)    18 (12.9%)    1 (0.7%)     0.033      0.030                                                      90 (21.2%)    20 (4.7%)    48 (21.1%)    10 (4.4%)    0.959      0.847
  Trismus                    6 (1.2%)         0 (0.0%)                  1 (0.9%)          0 (0.0%)     1          ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   9 (2.1%)      0 (0.0%)     2 (1.4%)      0 (0.0%)     0.858      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   5 (1.2%)      0 (0.0%)     1 (0.4%)      0 (0.0%)     0.607      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^
  Dysphagia                  7 (1.4)          0 (0.0%)                  1 (0.9%)          0 (0.0%)     0.981      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   11 (2.6%)     0 (0.0%)     0 (0.0%)      0 (0.0%)     0.074      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   8 (1.9%)      0 (0.0%)     0 (0.0%)      0 (0.0%)     0.056      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^
  Neck fibrosis              127 (26.0%)      9 (1.8%)                  26 (22.6%)        1 (0.9%)     0.449      0.741                                                      121 (28.9%)   10 (2.4%)    35 (25.0%)    2 (1.4%)     0.376      0.734                                                      124 (29.4%)   13 (3.1%)    52 (22.8%)    2 (0.9%)     0.077      0.133
  Xerostomia                 156 (32.0%)      18 (3.7%)                 37 (32.2%)        1 (0.9%)     0.966      0.208                                                      157 (37.5%)   14 (3.3%)    55 (39.3%)    4 (2.9%)     0.701      0.996                                                      132 (31.1%)   17 (4.0%)    74 (32.5%)    8 (3.5%)     0.729      0.751
  Cranial nerve palsy        31 (6.4%)        0 (0.0%)                  4 (3.5%)          0 (0.0%)     0.335      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   18 (4.3%)     0 (0.0%)     3 (2.1%)      0 (0.0%)     0.366      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^   20 (4.7%)     0 (0.0%)     11 (4.8%)     0 (0.0%)     0.951      ^[\*](#table-fn3-1758835920928214){ref-type="table-fn"}^
  Radiation encephalopathy   48 (9.8%)        3 (0.6%)                  10 (9.6%)         2 (1.7%)     0.709      0.532                                                      40 (9.5%)     3 (0.7%)     15 (10.7%)    0 (0.0%)     0.688      0.577                                                      41 (9.7%)     4 (0.9%)     28 (12.3%)    3 (1.3%)     0.301      0.967

CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; RT, radiotherapy.

No grade 3 or 4 toxicities were recorded.

In addition, in the low and intermediate-risk group, the incidence of grade 1--2 adverse events of vomiting (*p* \< 0.001 and *p* = 0.006, respectively), nausea (*p* = 0.002 and *p* \< 0.001, respectively), hyponatremia (*p* = 0.042 and *p* = 0.060, respectively) and late hearing toxicity (*p* = 0.002 and *p* = 0.033, respectively) were statistically different in the IC plus RT group and the CCRT group. Besides, in the low-risk group, a higher occurrence of renal (*p* = 0.062) and liver dysfunction (*p* = 0.012) was observed in the CCRT group than the IC plus RT group ([Table 2](#table2-1758835920928214){ref-type="table"}). Nevertheless, in the intermediate and high-risk groups, more patients in the IC plus RT group developed grade 1--2 hematological toxicities (leucopenia and neutropenia) than patients in the CCRT group ([Table 2](#table2-1758835920928214){ref-type="table"}).

Discussion {#section17-1758835920928214}
==========

To the best of our knowledge, the efficacy of IC followed by RT has not been fully investigated. In this study, we found that the survival benefit achieved by IC plus RT was comparable to CCRT in the low and intermediate-risk groups. Furthermore, patients in the IC plus RT group suffered from fewer treatment-related adverse events but survival rates in the IC plus RT group yielded to CCRT in the high-risk group.

Since the landmark Intergroup 0099 trial, studies concerning the interaction between the timing of chemotherapy and the effect on various endpoints have been ongoing. Chemoradiotherapy, including concurrent cisplatin chemoradiotherapy combined with/without either IC or adjuvant chemotherapy, has been widely applied to treat locoregionally advanced NPC. Recently, an increasing number of studies have demonstrated that adding IC to CCRT favorably improves the survival rate of patients with NPC. A large multicenter, randomized controlled phase III trial conducted by Zhang *et al.* has reported that the addition of IC to CCRT significantly improves the 3-year recurrence-free survival (85.3% *versus* 76.5%) and OS (94.6% *versus* 90.3%).^[@bibr14-1758835920928214]^ Another trial by Sun *et al.* has showed that the addition of TPF IC to concurrent chemoradiotherapy significantly improves failure-free survival in patients with locoregionally advanced NPC.^[@bibr15-1758835920928214]^ In daily clinical work, because of the increased treatment-related toxicities accompanying concurrent cisplatin chemotherapy, a certain proportion of patients refused to receive CCRT and underwent IC followed by RT alone. Moreover, the benefits of concurrent chemotherapy in the IMRT era have not been fully explored. A study evaluating the long-term survival outcomes and toxicity of 868 patients with NPC has demonstrated that concurrent chemotherapy does not improve the survival rates of patients with advanced locoregional disease. Compared with IMRT alone, IMRT plus concurrent chemotherapy increases the severity of acute toxicities.^[@bibr16-1758835920928214]^ According to Cao *et al*., concurrent chemotherapy does not improve survival rates for patients with stage T4 disease.^[@bibr17-1758835920928214]^ However, several meta-analyses and studies have shown that the survival benefit of chemotherapy primarily comes from the concurrent phase.^[@bibr18-1758835920928214][@bibr19-1758835920928214][@bibr20-1758835920928214]--[@bibr21-1758835920928214]^ Thus, the most effective way to combine chemotherapy with radiotherapy still needs further investigation.

Currently, there were only a few studies focusing on patients being administered IC plus RT alone. A retrospective study in 370 patients with locoregionally advanced NPC has reported that IC plus RT produces a superb outcome in terms of local control, regional control, metastasis-free survival, disease-free survival and OS rates.^[@bibr22-1758835920928214]^ Wei *et al.* also found that IC plus RT achieved favorable survival outcomes and had a lower incidence of toxicity.^[@bibr23-1758835920928214]^ One possible reason for these controversial results was that the therapeutic decisions in the aforementioned studies were simply based on the tumor-node-metastasis (TNM) stage. Given the biological heterogeneity of cancer, the present staging system remains inadequate for predicting NPC patient prognosis. Therefore, we developed three nomograms including age, gender, and the anatomical information on tumors and plasma EBV DNA levels to provide individualized estimates of potential OS, PFS and DMFS for patients with locoregionally advanced NPC. We then divided patients into three different risk groups categorized by the nomograms; this provided excellent discrimination in OS. Moreover, we explored the efficacy of IC plus RT and CCRT in different risk patients. We found that patients in the low and intermediate-risk groups achieved comparable OS, PFS and DMFS from IC plus RT when compared with CCRT. Furthermore, grade 3 or 4 toxicities were significantly less frequent in the IC plus RT group, except for hematological toxicities (leucopenia and neutropenia). We showed that patients treated with IC plus RT had improved treatment tolerability compared to patients treated with CCRT. Patient intolerance to these adverse effects limits the usefulness of CCRT. However, in the high-risk group, patients in the IC plus RT group had a worse OS and PFS. Hence, based on the results of our study, changing concurrent chemotherapy to IC is recommended for patients with a low or intermediate risk of treatment failure, but not for those in high-risk groups.

Our study has several limitations. First, this is a retrospective study in a single center; therefore, these results must be validated by other datasets and prospective studies. Second, the sample size of patients treated with IC plus RT in each risk group was relatively small. A larger sample size of patients is needed to evaluate the long-term outcomes of these patients. Third, the lack of quality of life data for the different treatment methods makes these results underpowered. In the future, a well-designed, multicenter, prospective, randomized study is needed to validate our results.

Conclusion {#section18-1758835920928214}
==========

In conclusion, our study demonstrated that, in the low and intermediate-risk groups, IC plus RT is an alternative treatment strategy to concurrent cisplatin chemoradiotherapy in patients with locoregionally advanced NPC. IC plus RT had no benefits in patients classified as high-risk patients. Thus, IC followed by RT alone was not recommended for patients with a high risk of treatment failure. The results of this study could widen the choice of the timing of chemotherapy offered to patients with NPC. Further investigation is necessary to confirm our findings.
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